Challenges in recognizing treatment-related neuroendocrine prostate cancer.

@article{Beltran2012ChallengesIR,
  title={Challenges in recognizing treatment-related neuroendocrine prostate cancer.},
  author={Himisha Beltran and Scott T Tagawa and Kyung ja Park and Philip J. Stephens and Matthew Ivan Milowsky and Juan Miguel Mosquera and Mark A. Rubin and Dominika E Nanus},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 36},
  pages={
          e386-9
        }
}
Introduction The development of neuroendocrine prostate cancer (NEPC) is associated with aggressive disease, frequent visceral metastases, and a poor prognosis. Although NEPC rarely arises de novo, the amount of neuroendocrine differentiation of prostate adenocarcinoma increases with disease progression and in response to androgen deprivation therapy. NEPC does not express the androgen receptor (AR) and is considered clinically hormone refractory. With the introduction of new highly potent AR… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 86 CITATIONS, ESTIMATED 48% COVERAGE

Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer

  • Oncogene
  • 2019
VIEW 9 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
VIEW 12 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2006
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

  • Averaged 9 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Common gene rearrangements in prostate cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 1 EXCERPT

Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2009
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…